Ultragenyx Pharmaceutical Inc (RARE)
41.90
-0.71
(-1.67%)
USD |
NASDAQ |
May 17, 16:00
41.90
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash and Short Term Investments (Quarterly): 412.08M for March 31, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 412.08M |
| December 31, 2023 | 577.21M |
| September 30, 2023 | 442.09M |
| June 30, 2023 | 551.98M |
| March 31, 2023 | 629.35M |
| December 31, 2022 | 747.76M |
| September 30, 2022 | 888.68M |
| June 30, 2022 | 542.80M |
| March 31, 2022 | 598.32M |
| December 31, 2021 | 740.20M |
| September 30, 2021 | 737.12M |
| June 30, 2021 | 845.76M |
| March 31, 2021 | 965.41M |
| December 31, 2020 | 1.202B |
| September 30, 2020 | 765.52M |
| June 30, 2020 | 813.42M |
| March 31, 2020 | 663.28M |
| December 31, 2019 | 755.23M |
| September 30, 2019 | 527.06M |
| June 30, 2019 | 618.29M |
| March 31, 2019 | 715.32M |
| December 31, 2018 | 459.71M |
| Date | Value |
|---|---|
| September 30, 2018 | 503.10M |
| June 30, 2018 | 547.13M |
| March 31, 2018 | 541.35M |
| December 31, 2017 | 234.49M |
| September 30, 2017 | 371.07M |
| June 30, 2017 | 399.65M |
| March 31, 2017 | 425.19M |
| December 31, 2016 | 380.15M |
| September 30, 2016 | 396.43M |
| June 30, 2016 | 391.80M |
| March 31, 2016 | 411.86M |
| December 31, 2015 | 437.00M |
| September 30, 2015 | 448.38M |
| June 30, 2015 | 326.03M |
| March 31, 2015 | 342.57M |
| December 31, 2014 | 187.49M |
| September 30, 2014 | 201.19M |
| June 30, 2014 | 153.27M |
| March 31, 2014 | 165.40M |
| December 31, 2013 | 53.38M |
| September 30, 2013 | 63.66M |
| December 31, 2012 | 86.19M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
412.08M
Minimum
Mar 2024
1.202B
Maximum
Dec 2020
701.15M
Average
700.20M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Insulet Corp | 751.20M |
| Sarepta Therapeutics Inc | 1.391B |
| FibroGen Inc | 177.60M |
| Apellis Pharmaceuticals Inc | 325.92M |
| Amylyx Pharmaceuticals Inc | 373.29M |